trending Market Intelligence /marketintelligence/en/news-insights/trending/dgy96s7WowE7oCnW-Mu7KA2 content esgSubNav
In This List

BioTime closes acquisition of Asterias Biotherapeutics

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


BioTime closes acquisition of Asterias Biotherapeutics

Alameda, Calif.-based BioTime Inc. completed its acquisition of biotechnology company Asterias Biotherapeutics Inc.

Under the all-stock deal, Asterias shareholders received 0.71 share of BioTime for each Asterias share held. Asterias owns about 16.2% of the combined company.

Asterias Biotherapeutics has filed for the delisting of its common shares on NYSE American following completion of the deal.

Fremont, Calif.-based Asterias develops cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer.